Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $12.2 million.

  • Mirum Pharmaceuticals' Accounts Payables rose 2746.99% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 2746.99%. This contributed to the annual value of $14.6 million for FY2024, which is 9711.43% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Accounts Payables stood at $12.2 million, which was up 2746.99% from $17.7 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Accounts Payables' 5-year high stood at $17.7 million during Q2 2025, with a 5-year trough of $4.9 million in Q1 2022.
  • Its 5-year average for Accounts Payables is $9.7 million, with a median of $9.2 million in 2021.
  • In the last 5 years, Mirum Pharmaceuticals' Accounts Payables surged by 19089.18% in 2021 and then tumbled by 3187.04% in 2024.
  • Mirum Pharmaceuticals' Accounts Payables (Quarter) stood at $9.2 million in 2021, then fell by 5.19% to $8.7 million in 2022, then decreased by 14.66% to $7.4 million in 2023, then soared by 97.11% to $14.6 million in 2024, then fell by 16.77% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $17.7 million for Q2 2025, and $11.6 million during Q1 2025.